Indications for Leukopoiesis Stimulants
In clinical practice, physicians frequently encounter conditions characterized by suppressed bone marrow hematopoiesis. A reduction in leukocyte count below 4,000/µL is termed leukopenia. A more severe condition marked by a sharp drop in granulocytes alongside a generalized reduction in white blood cells is known as agranulocytosis.
Under these conditions, the patient loses natural resistance to infectious agents. The primary etiologic factors of hematopoietic suppression include:
- Exposure to ionizing radiation (including X-ray and radiotherapy).
- Exposure to toxic substances.
- Adverse drug reactions (especially antineoplastic agents and antiviral drugs used in HIV treatment).
To prevent severe infectious complications, there is an urgent clinical need for the pharmacological stimulation of leukopoiesis.
Colony-Stimulating Factors (CSFs)
The most effective modern stimulants are recombinant human growth factor preparations. Based on their target cells, they are divided into four main groups:
- Granulocyte colony-stimulating factors (G-CSF): Selectively stimulate neutrophil production. A prominent representative is filgrastim. It regulates neutrophil production, accelerates their release into the bloodstream, and functionally activates these cells (enhancing phagocytosis and chemotaxis). A noticeable increase in neutrophil count is observed within the first 24 hours.
- Macrophage colony-stimulating factors (M-CSF): Stimulate monocyte production (precursors of tissue macrophages).
- Granulocyte-macrophage colony-stimulating factors (GM-CSF): Possess a broad spectrum of activity. They stimulate the proliferation of hematopoietic progenitor cells, increasing the formation of neutrophils, eosinophils, basophils, and monocytes. Key agents include molgramostim and sargramostim. Molgramostim also acts as an erythropoietin cofactor, additionally stimulating erythropoiesis.
- Interleukin-3 (IL-3): A universal (multipotential) growth factor.
CSF preparations are prescribed for post-chemotherapy leukopenia, bone marrow transplantation, myelodysplastic syndrome, and aplastic anemia. They are administered parenterally. When given subcutaneously, peak concentrations are reached in 3–4 hours.
Pyrimidine Derivatives and Other Agents
For milder forms of leukopenia, oral medications are appropriate. The main representatives of this group are methyluracil (hydroxymethyluracil) and pentoxyl.
Their pharmacodynamic effects are not limited to hematopoiesis:
- Moderate stimulation of leukopoiesis.
- Pronounced anti-inflammatory action.
- Acceleration of cellular regeneration processes (actively promoting wound healing).
Comparative profile: Pentoxyl irritates mucous membranes and frequently causes dyspeptic disorders. Methyluracil lacks this drawback and is significantly better tolerated. Other agents stimulating leukopoiesis include leukogen, batylol, and etaden (hydroxyethylaminoadenine).
Safety Profile and Side Effects
Potent pharmacological stimulation of the bone marrow by growth factors is predictably accompanied by specific adverse reactions:
- Flu-like syndrome: Fever, chills, muscle pain (myalgia), and characteristic bone pain (ossalgia). Bone pain is a direct consequence of active bone marrow stimulation.
- Gastrointestinal disturbances: Dyspepsia (nausea, vomiting, diarrhea), loss of appetite (anorexia).
- Neurological symptoms: Headache, dizziness, pronounced fatigue (asthenia).
- Respiratory and allergic reactions: Dyspnea, skin rash, pruritus.
- Specific effects of filgrastim: Dysuria and transient arterial hypotension.
- Local reactions: Pain at the injection site.